# Childhood Lyme disease (LD)

### **CANADIAN PAEDIATRIC SURVEILLANCE PROGRAM**

2305 St. Laurent Blvd. Ottawa, ON K1G 4J8 Tel: 613-526-9397, ext. 239 Fax: 613-526-3332

cpsp@cps.ca www.cpsp.cps.ca

# REPORTING INFORMATION (To be completed by CPSP staff) Report number: Month of reporting: Province: Today's date:

Please complete the following sections for the case identified above.

Strict confidentiality of information will be assured.

### CASE DEFINITION FOR CHILDHOOD LYME DISEASE

Report a patient less than 16 years of age with Lyme disease, meeting the following criteria:

Confirmed Lyme disease - Patient fulfills one of two conditions:

- 1. Clinical evidence of illness with laboratory confirmation
  - a. isolation of *Borrelia burgdorferi* from an appropriate clinical specimen
  - b. detection of B burgdorferi DNA by PCR in appropriate tissues

considered most important in reaching the diagnosis):

- 2. Clinical evidence of illness with a history of residence in, or visit to, an endemic area\* and with laboratory evidence of infection
  - positive serologic test using the two-tiered serological approach (i.e., ELISA followed by Western blot assays)

Probable Lyme disease - Patient fulfills one of two conditions:

- 1. Clinical evidence of illness without a history of residence in, or visit to, an endemic area\* and with laboratory evidence of infection
  - positive serologic test using the two-tiered serological approach (i.e., ELISA followed by Western blot assays)
- 2. Clinician-observed erythema migrans without laboratory evidence but with history of residence in, or visit to, an endemic area\*.

### **Exclusion criteria**

Confirmation of infection with a non-tick-borne disease, which fully explains symptoms. Cases diagnosed by methods and/or laboratories not recommended by the Public Health Agency of Canada or the US Centers for Disease Control and Prevention will be excluded.

\* An endemic area is defined as a locality in which reproducing populations of *Ixodes scapularis* or *Ixodes pacificus* tick vectors are present and transmission of *B burgdorferi* occurs at the location.

	Month first seen:
SECT	TION 1 – DEMOGRAPHIC INFORMATION
1.1	Date of birth: / / 1.2 Sex: Male Female
1.3	Province/territory of permanent residence:
1.4	Province/territory of diagnosis:
1.5	Postal code – First three digits only:
SECT	TION 2 – CLINICAL HISTORY
2.1	Date of onset of first symptoms: / /
2.2	Date of clinical diagnosis confirmed: / / DD MM YYYY
2.3	Main presenting symptoms (check all that apply and indicate with a cross in the right-hand column those you

Presentation	Yes No		Duration of the symptoms prior to diagnosis (days)	Symptoms important in diagnosis		
Single erythema migrans (EM) (at least 5 cm in diameter)						
Multiple EM						
Recurrent brief joint swelling						
Single joint arthritis						

### SECTION 2 - CLINICAL PRESENTATION (cont'd)

**SECTION 3 – LABORATORY DATA** 

Presentation	Yes	No	Duration of the symptoms prior to diagnosis (days)	Symptoms important in diagnosis
Polyarthritis				
Arthralgia				
Bell's palsy (facial paralysis)				
Other cranial neuropathy				
Radiculoneuropathy				
Meningitis/Lymphocytic meningitis				
Encephalitis/Encephalomyelitis				
Lyme carditis				
A-V heart block				
Palpitations/Arrhythmia				
Headache				
Fever				
Other relevant signs? (Please describe)				

3 1	Was the diagnosis made based only on clinical presentation (e.g.	FM) without laboratory testing

3.1	was the diagnosis made based only on clinical presentation (e.g., EM) without laboratory testing?
	Yes No Unknown If yes, skip to Section 4
3.2	Laboratory testing (check and complete all that apply)

3.2.1 Serological testing (enter all tests completed, including repeat tests – see options below table)

Serological Test	Date DD / MM / YYYY	Positive/ reactive	Negative/ non-reactive	Borderline/ weakly reactive	Unreadable	Not completed
				-		-
Other:						

Test options: ELISA, IFA, C6, Western Blot IgM, Western Blot IgG, CSF serology 3.2.2 Name(s) of the laboratory(ies) that completed sample testing: 3.2.3 PCR CSF\_\_\_ Other, specify: \_\_\_\_\_ Sample one: Tissue biopsy\_\_\_\_ Synovial fluid\_\_\_\_ Result: Positive\_\_\_ Negative\_\_\_ Indeterminate Sample two: Tissue biopsy\_\_\_ Synovial fluid\_\_ CSF\_\_ Other, specify: \_\_\_\_\_ Result: Positive\_\_\_ Negative\_\_\_ Indeterminate\_\_\_ Where was PCR completed? 3.2.4 Culture Sample one: Tissue biopsy\_\_\_ Synovial fluid\_\_ CSF\_\_ Other, specify: \_\_\_\_\_ Negative\_\_\_ Indeterminate\_\_\_\_ Result: Positive\_\_\_\_ Sample two: Tissue biopsy Synovial fluid\_\_\_ CSF\_\_ Other, specify: \_\_\_\_ Result: Positive\_\_\_ Negative\_\_\_ Indeterminate\_\_\_

SECT	ΓΙΟΝ 3 – LABORATORY	DATA	(cont'd	)					
3.3	Was any diagnostic test	ing cond	ducted c	outside of Canada? Yes	No Unknown	1			
	If yes, indicate: Labora	tory use	ed						
	Tests								
3.4	Case meets the following	g Lyme	disease	surveillance definition criteria	a:				
	Confirmed Proba	able 1	P	robable 2					
SECT	ΓΙΟΝ 4 – TREATMENT					Yes	No	Unknown	
4.1	Did the patient have a hi	istory of	a tick h	ite?					
4.2	Did the patient receive of	•							
	•		•	or Lyme disease symp	ntoms				
4.3	-			did he/she receive a prophyla					
	If yes, specify antibiotic:								
				ng Duration of treatment					
4.4	Was patient hospitalized			<u></u>	· ———————				
	If yes, duration of hospit								
4.5				efinitive treatment (does not in	nclude prophylaxis):				
		<u>'</u>		Dose	Frequency		Duratio	on (days)	
	Medication	Yes	No	(per kg body weight)	(per day)			r planned)	
	Amoxicillin								
	Doxycycline								
	Ceftriaxone								
	Anti-inflammatory								
	medication – Other:								
SECT	ΓΙΟΝ 5 – TREATMENT Ο	UTCON		mpletion of this section ma		o. If trea	tment	outcome is	
<b>5</b> 4	Did the metions become	-!-44		t yet known, please leave a	•				
5.1	Did the patient have persistent or recurrent symptoms after a recommended  Yes No Unknown								
	course of oral or IV antib								
	• • •				<del></del>				
<b>-</b> 0	If no, specify symptoms			h a subsequent source of ou					
5.2	Did the patient show improvement with a subsequent course of antibiotics?								
	ir no, specify symptoms	• ——			Duration:				
SECT	TION 6 - ENVIRONMENT	TAL EXI	POSUR	E HISTORY					
6.1	Did the patient reside in	or visit a	a Lyme	disease endemic or risk* <b>area</b>	<b>a in Canada</b> within 3	30 days	of the c	onset of the	
	symptoms? Yes No Unknown								
				da include parts of southern On (please see provided map)	ntario, Quebec, Nova	Scotia, I	New Bru	ınswick,	
	If yes: date:/_								
			10	/T	- O't -	/ D =!	_		
0.0				nty/ Town o					
6.2	•		•	disease endemic area <b>outsid</b>	ie of Canada Within	ას days	or the	onset of the	
	symptoms? Yes N		UNKNO\	WII					
	If yes: date:/_	YYY							
	USA E		А	sia					
	State			Town or City	/ Dark				

## SECTION 6 - ENVIRONMENTAL EXPOSURE HISTORY (cont'd) Did the patient have a history of a tick bite within 30 days of the onset of the symptoms? Yes No Unknown If no or unknown, go to question 6.4 If yes: Province \_\_\_\_/ County\_\_\_\_\_/ Town or City\_\_\_\_\_/ Park\_\_\_\_\_ In what type of environment was the patient when bitten by the tick(s)? (Check all that apply) 6.4 Forest\_\_\_\_ National or provincial park\_\_\_\_ Private or public garden\_\_\_\_ Municipal park\_\_\_\_ Farmland/Meadow Unknown Other, specify: Describe the activities that the patient was engaged in when they were exposed to the tick(s)? (Check all that apply) 6.5 Playing Dog walking Picnic Hiking Gardening Camping Sports Hunting/fishing\_\_\_\_ Unknown\_\_\_ Other, specify:\_\_\_\_ I agree to be contacted by the CPSP for further information on this questionnaire, especially about section 5, if not completed at the time of submission. I do not wish to be contacted by the CPSP for further information. SECTION 7 - REPORTING PHYSICIAN First name\_\_\_\_\_ Surname\_\_\_\_ Province\_\_\_\_ \_\_\_\_\_ Postal code\_\_\_\_\_ City\_\_\_\_ Telephone number\_\_\_\_\_\_ Fax number\_\_\_\_\_ E-mail \_\_\_\_\_ Date completed\_\_\_

Thank you for completing this questionnaire.

LD 2014/07

